Jacobs & Co’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.47M | Buy |
10,372
+95
| +0.9% | +$64.7K | 0.55% | 59 |
|
|
2026
Q1 | $7.94M | Sell |
10,277
-49
| -0.5% | -$37.5K | 0.78% | 53 |
|
|
2025
Q4 | $7.97M | Buy |
10,326
+164
| +2% | +$111K | 0.75% | 57 |
|
|
2025
Q3 | $5.71M | Sell |
10,162
-132
| -1% | -$74.6K | 0.55% | 63 |
|
|
2025
Q2 | $5.4M | Buy |
10,294
+244
| +2% | +$136K | 0.54% | 67 |
|
|
2025
Q1 | $6.37M | Buy |
10,050
+859
| +9% | +$591K | 0.68% | 63 |
|
|
2024
Q4 | $6.55M | Buy |
9,191
+64
| +0.7% | +$53.7K | 0.67% | 59 |
|
|
2024
Q3 | $9.59M | Sell |
9,127
-290
| -3% | -$323K | 0.96% | 44 |
|
|
2024
Q2 | $9.9M | Sell |
9,417
-59
| -0.6% | -$57.2K | 1.04% | 41 |
|
|
2024
Q1 | $9.12M | Sell |
9,476
-45
| -0.5% | -$42.8K | 0.97% | 47 |
|
|
2023
Q4 | $8.36M | Sell |
9,521
-161
| -2% | -$133K | 0.95% | 46 |
|
|
2023
Q3 | $7.97M | Sell |
9,682
-270
| -3% | -$212K | 0.99% | 45 |
|
|
2023
Q2 | $7.15M | Sell |
9,952
-295
| -3% | -$227K | 0.85% | 53 |
|
|
2023
Q1 | $8.42M | Sell |
10,247
-1,019
| -9% | -$769K | 1.04% | 44 |
|
|
2022
Q4 | $8.13M | Sell |
11,266
-416
| -4% | -$307K | 1.06% | 42 |
|
|
2022
Q3 | $8.05M | Buy |
11,682
+108
| +0.9% | +$68K | 1.16% | 40 |
|
|
2022
Q2 | $6.84M | Sell |
11,574
-697
| -6% | -$453K | 0.92% | 52 |
|
|
2022
Q1 | $8.57M | Sell |
12,271
-419
| -3% | -$265K | 0.95% | 52 |
|
|
2021
Q4 | $8.01M | Buy |
12,690
+341
| +3% | +$210K | 0.83% | 55 |
|
|
2021
Q3 | $7.47M | Buy |
12,349
+169
| +1% | +$105K | 0.86% | 54 |
|
|
2021
Q2 | $6.8M | Buy |
12,180
+145
| +1% | +$73.5K | 0.79% | 57 |
|
|
2021
Q1 | $5.69M | Buy |
12,035
+1,177
| +11% | +$573K | 0.7% | 61 |
|
|
2020
Q4 | $5.25M | Buy |
10,858
+1,750
| +19% | +$945K | 0.68% | 60 |
|
|
2020
Q3 | $5.1M | Buy |
9,108
+4,304
| +90% | +$2.61M | 0.74% | 58 |
|
|
2020
Q2 | $3M | Sell |
4,804
-1,160
| -19% | -$658K | 0.49% | 69 |
|
|
2020
Q1 | $2.91M | Buy |
+5,964
| New | +$2.46M | 0.56% | 68 |
|
|
2018
Q1 | – | Sell |
-31,557
| Closed | -$996K | – | 123 |
|
|
2017
Q4 | $996K | Sell |
31,557
-3,900
| -11% | -$1.58M | 0.18% | 91 |
|
|
2017
Q3 | $1.13M | Sell |
35,457
-2,440
| -6% | -$1.16M | 0.21% | 89 |
|
|
2017
Q2 | $1.21M | Sell |
37,897
-275
| -0.7% | -$120K | 0.24% | 88 |
|
|
2017
Q1 | $1.22M | Sell |
38,172
-14,032
| -27% | -$5.2M | 0.25% | 88 |
|
|
2016
Q4 | $1.49M | Buy |
52,204
+51,345
| +5,977% | +$19.5M | 0.32% | 82 |
|
|
2016
Q3 | $345K | Buy |
+859
| New | +$345K | 0.08% | 108 |
|
Other funds holding REGN
MCI
Jacobs & Co's REGN Position: Q2 2026 in Review
Jacobs & Co increased its Regeneron Pharmaceuticals (REGN) stake by 0.92% in Q2 2026, buying an estimated $64.7K and bringing the position to 10,372 shares worth $6.47M. The position accounts for 0.55% of the portfolio, ranked #59.
Jacobs & Co first reported a position in REGN in Q3 2016 and has held it in 32 quarters since. The position peaked at $9.9M in Q2 2024. 518 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Jacobs & Co held 10,372 shares of Regeneron Pharmaceuticals worth $6.47M as of Q2 2026.
- Jacobs & Co bought 95 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $64.7K.
- Regeneron Pharmaceuticals made up 0.55% of Jacobs & Co's portfolio in Q2 2026, its #59 holding.
- Jacobs & Co first reported a position in Regeneron Pharmaceuticals in Q3 2016 and has held it in 32 quarters since.
- Jacobs & Co's Regeneron Pharmaceuticals position peaked at $9.9M in Q2 2024.
- 518 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Jacobs & Co's 13F filing for Q2 2026, filed 9 Jul 2026.